Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.

Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L.

BMJ Open Respir Res. 2019 Mar 25;6(1):e000397. doi: 10.1136/bmjresp-2018-000397. eCollection 2019.

2.

Patient Registries in Idiopathic Pulmonary Fibrosis (IPF).

Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ.

Am J Respir Crit Care Med. 2019 Apr 29. doi: 10.1164/rccm.201902-0431CI. [Epub ahead of print]

PMID:
31034241
3.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW.

Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available.

PMID:
30950636
4.

Spontaneous ribosomal translocation of mRNA and tRNAs into a chimeric hybrid state.

Zhou J, Lancaster L, Donohue JP, Noller HF.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7813-7818. doi: 10.1073/pnas.1901310116. Epub 2019 Apr 1.

PMID:
30936299
5.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

6.

Enzyme colocalization in protein-based hydrogels.

Lancaster L, Bulutoglu B, Banta S, Wheeldon I.

Methods Enzymol. 2019;617:265-285. doi: 10.1016/bs.mie.2018.12.006. Epub 2019 Feb 8.

PMID:
30784405
7.

Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis.

Lancaster LH.

Multidiscip Respir Med. 2018 Dec 13;13:45. doi: 10.1186/s40248-018-0158-z. eCollection 2018. Review.

8.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

9.

BioTIME: A database of biodiversity time series for the Anthropocene.

Dornelas M, Antão LH, Moyes F, Bates AE, Magurran AE, Adam D, Akhmetzhanova AA, Appeltans W, Arcos JM, Arnold H, Ayyappan N, Badihi G, Baird AH, Barbosa M, Barreto TE, Bässler C, Bellgrove A, Belmaker J, Benedetti-Cecchi L, Bett BJ, Bjorkman AD, Błażewicz M, Blowes SA, Bloch CP, Bonebrake TC, Boyd S, Bradford M, Brooks AJ, Brown JH, Bruelheide H, Budy P, Carvalho F, Castañeda-Moya E, Chen CA, Chamblee JF, Chase TJ, Siegwart Collier L, Collinge SK, Condit R, Cooper EJ, Cornelissen JHC, Cotano U, Kyle Crow S, Damasceno G, Davies CH, Davis RA, Day FP, Degraer S, Doherty TS, Dunn TE, Durigan G, Duffy JE, Edelist D, Edgar GJ, Elahi R, Elmendorf SC, Enemar A, Ernest SKM, Escribano R, Estiarte M, Evans BS, Fan TY, Turini Farah F, Loureiro Fernandes L, Farneda FZ, Fidelis A, Fitt R, Fosaa AM, Daher Correa Franco GA, Frank GE, Fraser WR, García H, Cazzolla Gatti R, Givan O, Gorgone-Barbosa E, Gould WA, Gries C, Grossman GD, Gutierréz JR, Hale S, Harmon ME, Harte J, Haskins G, Henshaw DL, Hermanutz L, Hidalgo P, Higuchi P, Hoey A, Van Hoey G, Hofgaard A, Holeck K, Hollister RD, Holmes R, Hoogenboom M, Hsieh CH, Hubbell SP, Huettmann F, Huffard CL, Hurlbert AH, Macedo Ivanauskas N, Janík D, Jandt U, Jażdżewska A, Johannessen T, Johnstone J, Jones J, Jones FAM, Kang J, Kartawijaya T, Keeley EC, Kelt DA, Kinnear R, Klanderud K, Knutsen H, Koenig CC, Kortz AR, Král K, Kuhnz LA, Kuo CY, Kushner DJ, Laguionie-Marchais C, Lancaster LT, Min Lee C, Lefcheck JS, Lévesque E, Lightfoot D, Lloret F, Lloyd JD, López-Baucells A, Louzao M, Madin JS, Magnússon B, Malamud S, Matthews I, McFarland KP, McGill B, McKnight D, McLarney WO, Meador J, Meserve PL, Metcalfe DJ, Meyer CFJ, Michelsen A, Milchakova N, Moens T, Moland E, Moore J, Mathias Moreira C, Müller J, Murphy G, Myers-Smith IH, Myster RW, Naumov A, Neat F, Nelson JA, Paul Nelson M, Newton SF, Norden N, Oliver JC, Olsen EM, Onipchenko VG, Pabis K, Pabst RJ, Paquette A, Pardede S, Paterson DM, Pélissier R, Peñuelas J, Pérez-Matus A, Pizarro O, Pomati F, Post E, Prins HHT, Priscu JC, Provoost P, Prudic KL, Pulliainen E, Ramesh BR, Mendivil Ramos O, Rassweiler A, Rebelo JE, Reed DC, Reich PB, Remillard SM, Richardson AJ, Richardson JP, van Rijn I, Rocha R, Rivera-Monroy VH, Rixen C, Robinson KP, Ribeiro Rodrigues R, de Cerqueira Rossa-Feres D, Rudstam L, Ruhl H, Ruz CS, Sampaio EM, Rybicki N, Rypel A, Sal S, Salgado B, Santos FAM, Savassi-Coutinho AP, Scanga S, Schmidt J, Schooley R, Setiawan F, Shao KT, Shaver GR, Sherman S, Sherry TW, Siciński J, Sievers C, da Silva AC, Rodrigues da Silva F, Silveira FL, Slingsby J, Smart T, Snell SJ, Soudzilovskaia NA, Souza GBG, Maluf Souza F, Castro Souza V, Stallings CD, Stanforth R, Stanley EH, Mauro Sterza J, Stevens M, Stuart-Smith R, Rondon Suarez Y, Supp S, Yoshio Tamashiro J, Tarigan S, Thiede GP, Thorn S, Tolvanen A, Teresa Zugliani Toniato M, Totland Ø, Twilley RR, Vaitkus G, Valdivia N, Vallejo MI, Valone TJ, Van Colen C, Vanaverbeke J, Venturoli F, Verheye HM, Vianna M, Vieira RP, Vrška T, Quang Vu C, Van Vu L, Waide RB, Waldock C, Watts D, Webb S, Wesołowski T, White EP, Widdicombe CE, Wilgers D, Williams R, Williams SB, Williamson M, Willig MR, Willis TJ, Wipf S, Woods KD, Woehler EJ, Zawada K, Zettler ML, Hickler T.

Glob Ecol Biogeogr. 2018 Jul;27(7):760-786. doi: 10.1111/geb.12729. Epub 2018 Jul 24.

10.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

11.

Pediatric hepatic rhabdoid tumor: A rare cause of abdominal mass in children.

Kapral N, Melmer P, Druzgal CH, Lancaster L.

Radiol Case Rep. 2018 May 10;13(3):724-727. doi: 10.1016/j.radcr.2018.03.017. eCollection 2018 Jun.

12.

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL.

Lancet Respir Med. 2018 Aug;6(8):603-614. doi: 10.1016/S2213-2600(18)30135-8. Epub 2018 Jun 18.

PMID:
29891356
13.

Engineering enzyme microenvironments for enhanced biocatalysis.

Lancaster L, Abdallah W, Banta S, Wheeldon I.

Chem Soc Rev. 2018 Jul 17;47(14):5177-5186. doi: 10.1039/c8cs00085a. Review.

PMID:
29796541
14.

Mechanistic and phenotypic studies of bicarinalin, BP100 and colistin action on Acinetobacter baumannii.

Eales MG, Ferrari E, Goddard AD, Lancaster L, Sanderson P, Miller C.

Res Microbiol. 2018 Jul - Aug;169(6):296-302. doi: 10.1016/j.resmic.2018.04.005. Epub 2018 May 8.

PMID:
29751064
15.

Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease.

Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, Duffy J, Gaston B, Heller NM, Hemnes A, Henske EP, Jain R, Lahm T, Lancaster LH, Lee J, Legato MJ, McKee S, Mehra R, Morris A, Prakash YS, Stampfli MR, Gopal-Srivastava R, Laposky AD, Punturieri A, Reineck L, Tigno X, Clayton J.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):850-858. doi: 10.1164/rccm.201801-0168WS.

PMID:
29746147
16.

Signatures of local adaptation along environmental gradients in a range-expanding damselfly (Ischnura elegans).

Dudaniec RY, Yong CJ, Lancaster LT, Svensson EI, Hansson B.

Mol Ecol. 2018 Jun;27(11):2576-2593. doi: 10.1111/mec.14709. Epub 2018 May 19.

PMID:
29707847
17.

Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery.

Cole H, Bryan D, Lancaster L, Mawas F, Vllasaliu D.

Carbohydr Polym. 2018 Jun 15;190:248-254. doi: 10.1016/j.carbpol.2018.02.084. Epub 2018 Feb 27.

PMID:
29628245
18.

Unenhanced MRI as an Alternative to 99mTc-Labeled Dimercaptosuccinic Acid Scintigraphy in the Detection of Pediatric Renal Scarring.

Freeman CW, Altes TA, Rehm PK, de Lange EE, Lancaster L, Mugler JP 3rd, Patrie JT, Corbett S, Leiva-Salinas C, Flors L.

AJR Am J Roentgenol. 2018 Apr;210(4):869-875. doi: 10.2214/AJR.17.18379. Epub 2018 Feb 15.

PMID:
29446671
19.

Gestational Primary Hyperparathyroidism Due to Ectopic Parathyroid Adenoma: Case Report and Literature Review.

Horton WB, Stumpf MM, Coppock JD, Lancaster L, Dalkin AC, Liu Z, Chisholm CA, Smith PW, Kirk SE.

J Endocr Soc. 2017 Jun 30;1(9):1150-1155. doi: 10.1210/js.2017-00172. eCollection 2017 Sep 1.

20.

Bioinspired design of a hybrid bifunctional enzymatic/organic electrocatalyst for site selective alcohol oxidation.

Lancaster L, Hickey DP, Sigman MS, Minteer SD, Wheeldon I.

Chem Commun (Camb). 2018 Jan 11;54(5):491-494. doi: 10.1039/c7cc08548f.

PMID:
29260808
21.

Ribosome structural dynamics in translocation: yet another functional role for ribosomal RNA.

Noller HF, Lancaster L, Mohan S, Zhou J.

Q Rev Biophys. 2017 Jan;50:e12. doi: 10.1017/S0033583517000117. Review.

PMID:
29233224
22.

The ribosome moves: RNA mechanics and translocation.

Noller HF, Lancaster L, Zhou J, Mohan S.

Nat Struct Mol Biol. 2017 Dec 7;24(12):1021-1027. doi: 10.1038/nsmb.3505.

23.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

24.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

25.

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):94-103. doi: 10.1164/rccm.201704-0784OC.

PMID:
28787186
26.

Morphological evaluation of Merkel cells and small lamellated sensory receptors in the equine foot.

Bowker RM, Lancaster LS, Isbell DA.

Am J Vet Res. 2017 Jun;78(6):659-667. doi: 10.2460/ajvr.78.6.659.

PMID:
28541151
27.

Health Care Systems Support to Enhance Patient-Centered Care: Lessons from a Primary Care-Based Chronic Pain Management Initiative.

Elder CR, Debar LL, Ritenbaugh C, Rumptz MH, Patterson C, Bonifay A, Cowan P, Lancaster L, Deyo RA.

Perm J. 2017;21:16-101. doi: 10.7812/TPP/16-101.

28.

The thrombogenic activity of POSS silanols.

Lichtenhan JD, Hildebrandt DA, Lancaster LJ.

Dalton Trans. 2017 Jul 11;46(27):8788-8796. doi: 10.1039/c7dt00487g.

PMID:
28275773
29.

Range shifting species reduce phylogenetic diversity in high latitude communities via competition.

Fitt RN, Lancaster LT.

J Anim Ecol. 2017 May;86(3):543-555. doi: 10.1111/1365-2656.12655. Epub 2017 Apr 6.

PMID:
28217836
30.

Do group dynamics affect colour morph clines during a range shift?

Lancaster LT, Dudaniec RY, Hansson B, Svensson EI.

J Evol Biol. 2017 Apr;30(4):728-737. doi: 10.1111/jeb.13037. Epub 2017 Jan 28.

31.

Life history trade-offs, the intensity of competition, and coexistence in novel and evolving communities under climate change.

Lancaster LT, Morrison G, Fitt RN.

Philos Trans R Soc Lond B Biol Sci. 2017 Jan 19;372(1712). pii: 20160046.

32.

Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.

Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM.

Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24.

33.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
34.

Mindful Yoga Pilot Study Shows Modulation of Abnormal Pain Processing in Fibromyalgia Patients.

Carson JW, Carson KM, Jones KD, Lancaster L, Mist SD.

Int J Yoga Therap. 2016 Jan;26(1):93-100.

PMID:
27797669
35.

Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis.

Kropski JA, Young LR, Cogan JD, Mitchell DB, Lancaster LH, Worrell JA, Markin C, Liu N, Mason WR, Fingerlin TE, Schwartz DA, Lawson WE, Blackwell TS, Phillips JA 3rd, Loyd JE.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1423-1428. doi: 10.1164/rccm.201609-1820PP. No abstract available.

36.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

37.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

38.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

39.

FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.

Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, Brown KK, Flaherty KR, Wencel M, Wanger J, Neff T, Valone F, Stauffer J, Porter S.

Eur Respir J. 2016 May;47(5):1481-91. doi: 10.1183/13993003.01030-2015. Epub 2016 Mar 10.

40.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

41.

Gene expression under thermal stress varies across a geographical range expansion front.

Lancaster LT, Dudaniec RY, Chauhan P, Wellenreuther M, Svensson EI, Hansson B.

Mol Ecol. 2016 Mar;25(5):1141-56. doi: 10.1111/mec.13548. Epub 2016 Feb 21.

PMID:
26821170
42.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

43.

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.

Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES.

Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.

44.

Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.

Meyer KC, Danoff SK, Lancaster LH, Nathan SD.

Chest. 2015 Jul;148(1):242-252. doi: 10.1378/chest.14-2475. Review.

PMID:
26149553
45.

Consequences of inducing intrinsic disorder in a high-affinity protein-protein interaction.

Papadakos G, Sharma A, Lancaster LE, Bowen R, Kaminska R, Leech AP, Walker D, Redfield C, Kleanthous C.

J Am Chem Soc. 2015 Apr 29;137(16):5252-5. doi: 10.1021/ja512607r. Epub 2015 Apr 17.

PMID:
25856265
46.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.

47.

Rare variants in RTEL1 are associated with familial interstitial pneumonia.

Cogan JD, Kropski JA, Zhao M, Mitchell DB, Rives L, Markin C, Garnett ET, Montgomery KH, Mason WR, McKean DF, Powers J, Murphy E, Olson LM, Choi L, Cheng DS, Blue EM, Young LR, Lancaster LH, Steele MP, Brown KK, Schwarz MI, Fingerlin TE, Schwartz DA, Lawson WE, Loyd JE, Zhao Z, Phillips JA 3rd, Blackwell TS.

Am J Respir Crit Care Med. 2015 Mar 15;191(6):646-55. doi: 10.1164/rccm.201408-1510OC.

48.

Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease.

Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, McMahon FB, Worrell JA, Solus JF, Ware LB, Lee JW, Massion PP, Zaynagetdinov R, White ES, Kurtis JD, Johnson JE, Groshong SD, Lancaster LH, Young LR, Steele MP, Phillips Iii JA, Cogan JD, Loyd JE, Lawson WE, Blackwell TS.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):417-26. doi: 10.1164/rccm.201406-1162OC.

49.

How the ribosome hands the A-site tRNA to the P site during EF-G-catalyzed translocation.

Zhou J, Lancaster L, Donohue JP, Noller HF.

Science. 2014 Sep 5;345(6201):1188-91. doi: 10.1126/science.1255030.

50.

Direct measurement of the mechanical work during translocation by the ribosome.

Liu T, Kaplan A, Alexander L, Yan S, Wen JD, Lancaster L, Wickersham CE, Fredrick K, Noller H, Tinoco I, Bustamante CJ.

Elife. 2014 Aug 11;3:e03406. doi: 10.7554/eLife.03406. Erratum in: Elife. 2014;3:e04563. Fredrik, Kurt [corrected to Fredrick, Kurt].

Supplemental Content

Loading ...
Support Center